Extended-release buprenorphine is approved as a once-monthly subcutaneous injection for the treatment of moderate-to-severe OUD. A previous study cited by the study authors had suggested that a higher ...

The company raised its 2025 guidance, with Ciaffoni indicating, "We now expect total net revenue in 2025 to be up versus 2024, driven by SUBLOCADE growth of 10% at the midpoint." Preblick stated, "Our ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

The number of annual overdose deaths in Philadelphia dropped sharply last year and appears on track to continue falling, reflecting the ramped-up efforts of healthcare providers to help people in ...

The company reported 165,700 SUBLOCADE dispenses in Q2 2025, representing a 6% year-over-year increase and a 9% sequential improvement from Q1 2025. The trailing twelve-month patient count reached 171 ...

RICHMOND, Va., June 19, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting. A post hoc ...

The cost of Sublocade injection can vary based on several factors, including your insurance coverage. Copay assistance programs can also lower the price you’ll pay for Sublocade. As with all ...

CEO Mark Crossley stated that Q1 financial results were in line with expectations, despite a 6% year-on-year decline in total net revenue, largely driven by intensified competition in SUBOXONE Film ...

(The Center Square) – Lawmakers are hoping to expand and improve upon a 2015 law that offers grants to county jails treating inmates experiencing substance use disorders. Act 80 provides funding for ...

Indivior PLC, a global leader in addiction treatment, announced that the US Food and Drug Administration (FDA) has approved label changes for Sublocade including a rapid initiation protocol and ...